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LETTERS TO THE EDITORA CRITICAL APPRAISAL OF
PEXELIZUMAB TREATMENT
IN PATIENTS UNDERGOING
CORONARYARTERY BYPASS
GRAFTING
To the Editor:
We appreciate the recent article by
Smith and colleagues,1 in which they
reported that pexelizumab was associ-
ated with a nonsignificant reduction in
the primary postoperative composite
end point in patients enrolled in the
Pexelizumab for Reduction of Infarc-
tion and Mortality in Coronary Artery
Bypass Graft Surgery (PRIMO-
CABG) II trial. An exploratory analy-
sis of the combined PRIMO-CABG I
and II data sets, however, showed
a mortality benefit for high-risk surgi-
cal patients.1,2 Obviously, the authors
hypothesized a moderational model
regarding pexelizumab treatment,
which is only effective in high-risk
surgical patients. Recently, we have
established a mediational model re-
garding the pexelizumab treatment in
patients with severe coronary artery
disease undergoing primary coronary
revascularization on the basis of the re-
sults of the experiment by Røger and
colleagues3 and the mathematic esti-
mates of the relative risks of death.4
Our hypothesis is that pexelizumab
may cause platelet aggregation, lead-
ing to postprocedural myocardial in-
farction and death. On the other
hand, pexelizumab would reduce
myocardial reperfusion injury after re-
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dependent on the condition of ade-
quate antithrombotic therapy.5
As we know, more high-risk surgi-
cal patients were enrolled in
PRIMO-CABG II than in PRIMO-
CABG I, and the moderational model
failed to show better effectiveness of
pexelizumab in PRIMO-CABG II
than in PRIMO-CABG I.5 We explain
the results yielded by the mediational
model by positing that heparinization
during coronary artery bypass grafting
may be a pivotal confounder between
these 2 trials. Clinically, the activated
clotting time should be maintained at
longer than 450 seconds for patients
undergoing coronary artery bypass
grafting with cardiopulmonary bypass
circuits, or longer than 250 seconds
for those undergoing operation with
heparin-bonded cardiopulmonary by-
pass circuits.5 Thus to counteract the
platelet aggregation effect of pexeli-
zumab without adequate antiplatelet
therapy during coronary artery bypass
grafting may require a large amount of
heparin to achieve longer activated
clotting time, aiming to suppress the
thrombin activity. There were, how-
ever, no data regarding the use of hep-
arin and the target activated clotting
time during coronary artery bypass
grafting in either PRIMO-CABG I or
PRIMO-CABG II.5 Of note, both
PRIMO-CABG I and PRIMO-CABG
II were conducted in North America
and Western Europe, with the former
trial being held at 205 hospitals from
January 2002 to February 2003 and
the latter trial being held at 249 hospi-
tals from June 2004 to July 2005. In
time, heparin-bonded cardiopulmo-
nary bypass circuits may replace tradi-
tional cardiopulmonary bypass
circuits to become the main option
for patients undergoing coronary ar-
tery bypass grafting in the Western
countries, because their safety has
been demonstrated by reductions in
the amount of perioperative heparin
use and in the number of postoperative
bleeding events. Accordingly, there
may be a bias between PRIMO-ardiovascular Surgery c August 2011CABG I and PRIMO-CABG II if the
unbalanced use of heparin-bonded
cardiopulmonary bypass circuits is
taken into account.
In our opinion, a retrospective
survey regarding the types of cardio-
pulmonary bypass circuits used in
PRIMO-CABG I and PRIMO-
CABG II is suggested. It would be
useful to estimate the odds ratios for
the primary composite end point
with different cardiopulmonary by-
pass circuits in a multiple regression
analysis.
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